ETF Holdings Breakdown of ABCL

ABCL institutional holdings

The adjusted close for ABCL on 2025-11-11 was 4.01

The following institutional investment holdings of ABCL have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	259,600	USD 1,040,996 -0.5%	4.01
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	191,905	USD 769,539 -0.5%	4.01
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	191,905	USD 769,539 -0.5%	4.01
Total =		643,410	USD 2,580,074

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with ABCL

Analysts Set AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target at $8.75

AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) has been given a consensus recommendation of “Buy” by the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-05 02:08:56

AbCellera Biologics (NASDAQ:ABCL) Reaches New 12-Month High After Analyst Upgrade

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday after KeyCorp raised their price target on the stock from $5.00 to $10.00. KeyCorp currently has an overweight rating on the stock. AbCellera Biologics traded as high as $4.40 and last traded at $4.24, with […] - 2025-07-16 02:26:59

AbCellera Biologics (NASDAQ:ABCL) Raised to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of AbCellera Biologics (NASDAQ:ABCL – Free Report) to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) […] - 2025-07-10 03:08:44

Squarepoint Ops LLC Purchases 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)

Squarepoint Ops LLC lifted its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 333.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 57,685 shares of the company’s stock after acquiring an additional 44,367 shares during the quarter. Squarepoint Ops LLC’s holdings in AbCellera Biologics were worth $169,000 as […] - 2025-06-09 04:52:49

AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Position Lifted by Millennium Management LLC

Millennium Management LLC boosted its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 96.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,482,715 shares of the company’s stock after purchasing an additional 728,828 shares during the period. Millennium Management LLC’s holdings in […] - 2025-05-30 04:55:02

AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $10.00 by Analysts at Truist Financial

AbCellera Biologics (NASDAQ:ABCL – Free Report) had its price target trimmed by Truist Financial from $28.00 to $10.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other analysts also recently issued reports on the stock. Benchmark reaffirmed a “hold” rating on shares of AbCellera […] - 2025-05-19 02:16:53

Walleye Capital LLC Sells 241,881 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)

Walleye Capital LLC decreased its position in AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 94.2% during the 4th quarter, Holdings Channel reports. The firm owned 15,000 shares of the company’s stock after selling 241,881 shares during the period. Walleye Capital LLC’s holdings in AbCellera Biologics were worth $44,000 at the end of the most […] - 2025-04-29 05:24:53

Federated Hermes Inc. Reduces Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Federated Hermes Inc. reduced its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) by 59.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 916,237 shares of the company’s stock after selling 1,366,459 shares during the quarter. Federated Hermes Inc.’s holdings in AbCellera Biologics were worth $2,685,000 at the end of […] - 2025-04-14 05:15:08

Reviewing AbCellera Biologics (NASDAQ:ABCL) & Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings. Analyst Recommendations This is a summary of recent […] - 2025-03-11 04:47:14

Benchmark Reaffirms Hold Rating for AbCellera Biologics (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “hold” rating reissued by stock analysts at Benchmark in a research report issued on Monday,Benzinga reports. ABCL has been the subject of a number of other reports. KeyCorp reduced their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” […] - 2025-03-05 04:56:51

AbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Up 6.8% in January

AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 18,430,000 shares, an increase of 6.8% from the January 15th total of 17,260,000 shares. Based on an average daily trading volume, of 3,150,000 […] - 2025-02-17 04:10:55

Back to Listing

Disclaimer